CymaBay Therapeutics to Present at Upcoming Investment Conferences

Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) will be participating in three upcoming conferences: UBS Biopharma Conference on November 8-9th, Piper Sandler 35th Annual Healthcare Conference on November 28-30th, and Evercore ISI 6th Annual HealthCONx Conference on November 28-30th. The management team will engage in fireside chats and webcasts during these events.

NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9^th in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30^th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30^th, in Miami, Florida.

UBS Biopharma Conference
Date:	Wednesday, November 8
Time:	11:30am Eastern Time, Fireside Chat
Webcast:	http://ir.cymabay.com/events
Piper Sandler 35th Annual Healthcare Conference
Date:	Tuesday, November 28
Time:	2:00pm Eastern Time, Fireside Chat
Webcast:	http://ir.cymabay.com/events
Evercore ISI 6th Annual HealthCONx Conference
Date:	Wednesday, November 29
Time:	1:20pm Eastern Time, Fireside Chat
Webcast:	http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), Priority Medicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class investigational treatment for people with PBC. Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families, and communities we serve. To learn more, visit www.cymabay.com and follow us on X (formerly Twitter) and LinkedIn.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Theresa Dolge
Evoke Kyne
(609) 915-2156
Theresa.Dolge@evokegroup.com

Investor Relations Contact:

PJ Kelleher
LifeSci Advisors, LLC
(617) 430-7579
pkelleher@LifeSciAdvisors.com

FAQ

Which conferences will CymaBay Therapeutics be participating in?

CymaBay Therapeutics will be participating in the UBS Biopharma Conference, the Piper Sandler 35th Annual Healthcare Conference, and the Evercore ISI 6th Annual HealthCONx Conference.

When will the UBS Biopharma Conference take place?

The UBS Biopharma Conference will take place on November 8-9th.

When will the Piper Sandler 35th Annual Healthcare Conference and the Evercore ISI 6th Annual HealthCONx Conference take place?

The Piper Sandler 35th Annual Healthcare Conference and the Evercore ISI 6th Annual HealthCONx Conference will both take place on November 28-30th.

What type of sessions will the management team of CymaBay Therapeutics participate in?

The management team will engage in fireside chats during the conferences.

Will there be webcasts available for these events?

Yes, webcasts will be available for all the conferences. The webcast links can be found on the CymaBay Therapeutics website.